Evaxion to announce business update and full year 2025 financial results on March 5, 2026
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) will provide a business update and report its full year 2025 financial results on March 5, 2026 before Nasdaq opening. Executive Management will host a conference call and webcast at 14:30 CET / 08:30 EST.
Registration is required to join the call for dial-in numbers and PIN; the webcast will be accessible live and a recording will be posted on the company website shortly after the event.
Positive
- None.
Negative
- None.
News Market Reaction – EVAX
In the Mar 2 session, EVAX gained 0.32%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Platform expansion | Positive | -1.5% | Expanded AI-Immunology™ into autoimmune diseases with runway unchanged into H2 2027. |
| Jan 07 | Investor conference | Positive | +6.7% | Planned 2026 milestone presentation and corporate update at Biotech Showcase. |
| Dec 19 | Collaboration update | Negative | -18.3% | MSD declined EVX-B2 option; Evaxion retained rights and potential new partner search. |
| Dec 06 | Preclinical data | Positive | +19.6% | New EVX-04 AML vaccine data showed strong T-cell responses and prevented tumor growth. |
| Nov 20 | Preclinical data | Positive | +9.4% | EVX-V1 CMV program showed immune responses and reduced viral spread in models. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News on clinical data and pipeline progress has often coincided with positive price moves, while broader strategic platform updates have seen at least one divergence with a negative reaction.
Over the last few months, Evaxion has focused on AI-Immunology™ platform expansion and vaccine pipeline updates. Positive preclinical data for programs like EVX-04 and EVX-V1 saw strong gains of 9–20%, while the MSD collaboration update led to an 18.26% decline. A January 2026 milestones presentation generated a 6.73% rise, but the platform expansion into autoimmune disease in H2 2026 coincided with a modest -1.54% move. Today’s earnings-date announcement fits into this pattern of scheduled investor communications.
Key Terms
nasdaq cm financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM.
Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions.
To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.
To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development
We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
